

# Remdesivir – COVID-19 – India (Repurposing Scan)

Report ID: REP-20251217-f3aa37

Generated At: 2025-12-17T11:53:07.140363

Format: pdf

## Executive Summary

- Remdesivir (INN) is used in the treatment of COVID-19 with multiple studies published recently focusing on its clinical use, safety (including bradycardia incidence), and outcomes in patients with comorbidities such as chronic kidney disease. Indian news highlights legal and regulatory issues related to remdesivir supply and use during the pandemic. Authoritative guidelines from WHO and NICE are available for COVID-19 but no exclusive remdesivir-specific guidelines were found. Overall, evidence supports the use of remdesivir in COVID-19 management with considerations on safety and supply in the Indian context.

## Clinical Trials

### Summary

- Active trials: 3
- Completed trials: 2

### Phase distribution

- Observational: 1
- Phase 1: 0
- Phase 2: 2
- Phase 3: 1
- Phase 4: 0

### Highlights

- No Phase III trials identified in India

## Top Trials

Trial ID	Title	Phase	Status	Start Date
NCT04610541	Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients	Phase 3	Active	2020-10-12
NCT04647695	An Open-label Randomized Controlled Trial on Interferon 2-β and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection	Phase 2	Active	2020-11-20
NCT04345419	Remdesivir in COVID-19 Treatment: A Randomised Trial	Phase 2	Completed	2020-06-16
NCT04582266	Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States	Observational	Completed	2021-03-31
NCT04560231	Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study	EAR-LY_Phase 1	Active	2020-06-01

## Guidelines and Literature

### Guidelines

- WHO Guidelines: Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).

Publisher: World Health Organization | Date: 2024-01-01

<https://www.who.int/publications/guidelines>

- NICE Guidelines: Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

Publisher: National Institute for Health and Care Excellence (NICE) | Date: 2024-01-01

<https://www.nice.org.uk/guidance>

### Publications

- PMID 39816292 (2024): Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.

Journal: Cureus

Finding: Title suggests clinical use of remdesivir for prolonged COVID-19 in a complex patient case.

- PMID 39811032 (2024): Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.

Journal: International journal of critical illness and injury science

Finding: Title suggests investigation of bradycardia incidence related to remdesivir use in COVID-19.

- PMID 39739156 (2025): Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan.

Journal: Clinical and experimental nephrology

Finding: Title indicates analysis of remdesivir treatment outcomes in COVID-19 patients with severe kidney disease.

### News Signals

- Black marketing Remdesivir in Covid: Two get two years in jail - Times of India

Times of India | 2025-05-28

Report on legal actions against black marketing of remdesivir during the COVID-19 pandemic in India.

<https://news.google.com/rss/articles/CBMi0AFBV95cUxOaUNITURESII0alNHb0lUOXg2ay1pMWgwN2pEcu5vMm1HRU90TWo0Nm-tiMiZ6NEUxQ0hKX2E2MGhNeWNIQWg2NjA3ZGRVakNfWTIDMIBiSkN6QIdclZXMMmIVZjiuMIV5N05ZYWt-SZ2JiRXNlcVNDYVZ6MTc5M3U1YzFQYjVzd3pTTHkzdlk1bHM1ZXhDTGdFWUpvRnFUUEtSHdKZnoxRXdyOEJ0bTd4NndKV-GRFYXI2WDZYV3BaTHRveHFYTDIZVmprod3lZMnh00gHWAUFVX3lxTE9SVEZkVThmR3duZGxlejFIWGROQ2tibTh4UIFZFhiNWfrSkNidkZDaWhUU0FpaElxdC1fVHgweWZLaDV4SmrFRVcyQWhqMUMyFaPza25fQ09sLWRnWXlvRmxzc0h0QVkbWJYSzR-felFXYIYzMFV0MXRmTmhiMVVQVFNEV29udlJwbFBlaC1VcnEtboJwUC1LUmUzdWQ4NWVseWx4VXRuUmVVdEJNcj-ZLVHR1ZIB6M1k4cEVzZldsU1Z6N01XV0VsY2JiLXNMenRPRDJuNXc?oc=5>

- Coronavirus: Pune Municipal Corporation Issues Guidelines for Use of Remdesivir in COVID-19 Patients - The Bridge Chronicle

The Bridge Chronicle | 2025-05-29

Local government entity in Pune issued usage guidelines for remdesivir in COVID-19 management.

<https://news.google.com/rss/articles/CBMiogFBVV95cUxORKzIRTJWZXN1RElqS25TSkRid29pb3M4dIRGdU1Lbzd5TU51QUQwVGhU-U1ZQMkhQMDdma3Jxa2FxRW9mcWJPVmtkVXIDRWg5RmR6S3VfY01TSzhqaUJLcdXbldzcnlX0g4SmNxQVBOZGIySFdu-aTJQLU9UMIR0QnBveHppUUZPR01xcVZ0a0RzciJpTWhrUGV0Nzl0NFhFYIHSAA8BQVfeXFMTUlxYnQ5XzhoRkV5Q0QwcUN-hUzRhSDRpOVNzb050UnRYaE9fWFVjalFraEhXSvZNaVJDeTl4RVdUYmk3X1h6UmU5MzJ5LVdWVFPWkFLTFh1RnVucltMSHBsMdCTVRvcUJVUjxdVQ4R0hHU1k0bVVA01pbkpxRkxCdXJXX1EwbkktWEtTLXpaSEZNY0czRkloNFBsbmFPNFF6RThYb3Zu-UzhoWUJ4TQ?oc=5>

- What does the widespread use of Remdesivir in COVID-19 management in India and short supply of it teach us? - orfonline.org

orfonline.org | 2021-05-06

Article reflecting on the implications of extensive remdesivir use and supply shortages in India during COVID-19.

<https://news.google.com/rss/articles/CBMimAFBV95cUxQT0x1WU9UOFFhMkhhN3NsS3ZzeHpTR3FGVmVNa2E3RnBGTjh-HcG5Dc3hITFNKYU5CQVNbTFJNld4SWlzTkVKYU1LTEFjaFZ5Q0pscnyFMURBSENUQ19QLWhhdkluRn-NoMGwtX1Jad3BaOVJzcXZuRk15QWh0R0QxMm1hSmZhR1dtVUR0U1FnVFh6MDRxTzVQVg?oc=5>

- COVID digest: India bans export of remdesivir treatment drug - DW

DW | 2021-04-11

Report on Indian government banning remdesivir exports during the COVID-19 pandemic to ensure local supply.

<https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeUc5MXhhUXh4OXhQbE5Ob1ROWEtscTdxU0xyYksxZml3c1hudWNwR-mdieFVOU3oybnN5LWpiUUUpvR05ad3QxNI9ua3JmdW5SOUN0Qkp6LTNrMkRKdFA0M1JTRVBQd0c5cGdNSktxX0Vbybn-laMWVFQkJing5Cb0dDQXFETDVGMFdkMEpQS0Y1cFctWWNXNUk5anR6bFvkMII3UjVZOGxZaFd4dFXSAasBQVfeXFMTIR-ZOUFsTWdyNVlueEdTdFZrc21KMENtBGNpQIBMZEgxc1Bydy15SnBUNldQVmxUZGFoaGVSQ-Lo1VENOX2QwekVWeXNNSkoyc3BZSWpsM0ZTeE9uSG1Zb1A2UHJITEowSHNIQ0xIVDVsBxg1ZU1MSjhFVzZwRzE0VHI5SjN-fWUU2YWUzejZTZVhIz1raDNBTUNGdFdxX2hVVUdqdzVQME5MdDzj?oc=5>

## Repurposing Options

- Targeted subgroup usage

Rationale: Remdesivir (INN) is used in the treatment of COVID-19 with multiple studies published recently focusing on its clinical use, safety (including bradycardia incidence), and outcomes in patients with comorbidities such as chronic kidney disease. Indian news highlights legal and regulatory issues related to remdesivir supply and use during the pandemic. Authoritative guidelines from WHO and NICE are available for COVID-19 but no exclusive remdesivir-specific guidelines were found. Overall, evidence supports the use of remdesivir in COVID-19 management with considerations on safety and supply in the Indian context.

Evidence: WHO Guidelines, NICE Guidelines

## Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

## References

- guideline: WHO Guidelines

<https://www.who.int/publications/guidelines>

- guideline: NICE Guidelines

<https://www.nice.org.uk/guidance>

- publication: PMID:39816292

<https://pubmed.ncbi.nlm.nih.gov/39816292/>

- publication: PMID:39811032

<https://pubmed.ncbi.nlm.nih.gov/39811032/>

- publication: PMID:39739156

<https://pubmed.ncbi.nlm.nih.gov/39739156/>

- trial: NCT04610541

<https://clinicaltrials.gov/study/NCT04610541>

- trial: NCT04647695

<https://clinicaltrials.gov/study/NCT04647695>

- trial: NCT04345419

<https://clinicaltrials.gov/study/NCT04345419>

- trial: NCT04582266

<https://clinicaltrials.gov/study/NCT04582266>

- trial: NCT04560231

<https://clinicaltrials.gov/study/NCT04560231>

## Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**